The DSMB’s review of the efficacy data is still pending.
Northwest Biotherapeutics chief technical officer Dr. Marnix Bosch noted the company is pleased with the recommendation of the DSMB to continue the trial as planned.
"This is an important step in the ongoing progress of our Phase III trial," Dr Bosch added.